Spirit 2
Spirit 2
STI571 Prospective International RandomIsed Trial 2 – A phase III, prospective randomised comparison of imatinib 400mg daily versus dasatinib 100mg in patients with newly-diagnosed chronic phase chronic myeloid leukaemia.
- Study stage: Closed
- Sponsor: The Newcastle Upon Tyne Hospitals NHS Foundation Trust
- Funder: IIT (Bristol Myer Sqibb)
- Therapeutic area: Cancer and Neoplasm
- Type of study: CTIMP
Aim: To compare 5 year event free survival between the treatment arms.
- Clinical Phase: III
- Population: Adult
- Design: RCT
- Setting: Secondary Care
- Planned Sample Size: 810